search
Back to results

Clinical Application of the Medyria TrackCath System in Endovascular Repair of Abdominal Aortic Aneurysms (AAA) (ACCESS)

Primary Purpose

Aortic Aneurysm, Abdominal, Aortic Aneurysm, Thoracoabdominal, Acute Renal Failure

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Medyria TrackCath System
Sponsored by
Medyria AG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Aneurysm, Abdominal focused on measuring Endovascular aneurysm repair, EVAR, AAA, Cannulation, Blood Flow Velocity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient has signed and understood the approved Informed Consent form and is able to meet the proposed study proceedings (CIP).
  • Patient is ≥18 years of age
  • Need for standard or complex EVAR of AAA according to the relevant guidelines:
  • Asymptomatic aneurysms with a diameter > 55mm in men and > 50 mm in woman
  • Aneurysm-growth exceeds 10mm/year
  • Patient requires at least one cannulation during which requires at least one cannulation (e.g. fenestration of endograft, side-branch and/or contralateral leg of endograft)

Exclusion Criteria:

  • Patient is generally contraindicated for EVAR
  • Patient requires an emergency surgery
  • Patient with an increased risk of aneurysm rupture or saccular aneurysm, aneurysm with isolated wall protuberances or penetrating aortic ulcer
  • Patient with a dissecting acutely ruptured or leaking aneurysm or an acute vascular injury caused by a trauma
  • Patient with stroke or transient ischemic attack (TIA) within the last 6 months prior to baseline
  • Patient with myocardial infarction (MI) with the last 3 months prior to baseline
  • Patient with acute or chronic renal failure (including dialysis); Creatinine > 2.00 mg/dl or > 182 µmol/L
  • Patient with co-morbidities that constitutes an unacceptable risk (for example chronic obstructive pulmonary disease (COPD), liver failure, immunosuppression, polyneuropathy and hematological diseases)
  • Patient with bleeding history or coagulopathy
  • Patient with contraindication or allergies to take anticoagulants, antiplatelet drugs or contrast media
  • Life expectancy of less than 5 years
  • Female patient that is pregnant, is planning on becoming pregnant in the next month or is breastfeeding
  • Patient with inability to obtain vascular access
  • Patient has an active local or systemic infection
  • Patient is currently participating in another investigational study where the endpoints have not yet been achieved
  • Patient has a mental illness, and/or been diagnosed as clinically depressed or belongs to a vulnerable population (e.g., prisoner, severe drug abuser, developmentally disabled) that would compromise the ability to provide informed consent.
  • Patient has an obstructed or inadequate vasculature by means of tortuous anatomy hindering the TC catheter to reach target orifice(s)
  • Patient has an elevated risk of plaque dislodgment.

Sites / Locations

  • Universitätsklinikum RWTH Aachen
  • Heinrich-Heine University Düsseldorf
  • Universitäres Herzzentrum Hamburg
  • Universitätklinikum Leipzig

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single arm

Arm Description

TrackCath

Outcomes

Primary Outcome Measures

Procedural Success Rate
Successful TrackCath delivery of the distal end of the guidewire or of the 4 French catheter to the selected targeted orifice(s).
Primary Safety (All SADEs)
Occurrence of Serious Adverse Device Effects (SADE)

Secondary Outcome Measures

Secondary Safety (All AEs)
All Adverse Events
Procedural Parameters (contrast dye)
Amount of contrast dye used (ml)
Procedural Parameters (procedural times)
Exposure time to X-ray (min); total duration of the procedure (min); duration of the target orifice identification and cannulation (min).
Procedural Parameters (Blood flow velocity)
Blood flow velocity changes between above orifice and at orifice (m/s).
Surgeon satisfaction rate
Surgeon satisfaction on the use of the TrackCath catheter and the Blood Flow Velocity sensor, expressed on a scale from 1 (very bad) to 5 (very good).

Full Information

First Posted
November 14, 2019
Last Updated
December 5, 2019
Sponsor
Medyria AG
Collaborators
StatConsult Gesellschaft für klinische und Versorgungsforschung mbH, Axxos GmbH, Worldwide Clinical Trials, Medical Mind RCS GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT04190979
Brief Title
Clinical Application of the Medyria TrackCath System in Endovascular Repair of Abdominal Aortic Aneurysms (AAA)
Acronym
ACCESS
Official Title
Clinical Application of the Medyria TrackCath System in Endovascular Repair of Abdominal Aortic Aneurysms (AAA) - A Prospective Multi-centre Clinical Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
March 17, 2018 (Actual)
Primary Completion Date
February 25, 2019 (Actual)
Study Completion Date
February 25, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medyria AG
Collaborators
StatConsult Gesellschaft für klinische und Versorgungsforschung mbH, Axxos GmbH, Worldwide Clinical Trials, Medical Mind RCS GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pre-market, single-arm, prospective, open-label, multi-center clinical trial aimed at assessing the safety and the performance of the Medyria TrackCath system in patients undergoing endovascular intervention.
Detailed Description
Pre-market, single-arm, prospective, open-label, multi-center clinical trial aimed at assessing the safety and the performance of the Medyria TrackCath system in patients above the age of 18 years who have been diagnosed with aneurysms in the thoracoabdominal (TAAA) or abdominal (AAA) aorta and require endovascular intervention. The TrackCath System is a non-implantable disposable device, intended to measure real-time changes in the Blood Flow Velocity and to provide a pathway for delivering third-party guidewires and/or catheters. Following patient consent, data is collected until discharge. To reach 80% power, a total number of 32 patients (minimum 42 target orifices) is scheduled, including a minimum of 8 roll-in patients for the training phase, which comprises at least two successful cases per center.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Aneurysm, Abdominal, Aortic Aneurysm, Thoracoabdominal, Acute Renal Failure, Acute Kidney Injury, Acute Kidney Failure, Acute Renal Insufficiency
Keywords
Endovascular aneurysm repair, EVAR, AAA, Cannulation, Blood Flow Velocity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single arm
Arm Type
Experimental
Arm Description
TrackCath
Intervention Type
Device
Intervention Name(s)
Medyria TrackCath System
Intervention Description
The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.
Primary Outcome Measure Information:
Title
Procedural Success Rate
Description
Successful TrackCath delivery of the distal end of the guidewire or of the 4 French catheter to the selected targeted orifice(s).
Time Frame
Intra-operative
Title
Primary Safety (All SADEs)
Description
Occurrence of Serious Adverse Device Effects (SADE)
Time Frame
Up to discharge (expected to be within 1 month)
Secondary Outcome Measure Information:
Title
Secondary Safety (All AEs)
Description
All Adverse Events
Time Frame
Up to discharge (expected to be within 1 month)
Title
Procedural Parameters (contrast dye)
Description
Amount of contrast dye used (ml)
Time Frame
Intra-operative
Title
Procedural Parameters (procedural times)
Description
Exposure time to X-ray (min); total duration of the procedure (min); duration of the target orifice identification and cannulation (min).
Time Frame
Intra-operative
Title
Procedural Parameters (Blood flow velocity)
Description
Blood flow velocity changes between above orifice and at orifice (m/s).
Time Frame
Intra-operative
Title
Surgeon satisfaction rate
Description
Surgeon satisfaction on the use of the TrackCath catheter and the Blood Flow Velocity sensor, expressed on a scale from 1 (very bad) to 5 (very good).
Time Frame
Intra-operative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient has signed and understood the approved Informed Consent form and is able to meet the proposed study proceedings (CIP). Patient is ≥18 years of age Need for standard or complex EVAR of AAA according to the relevant guidelines: Asymptomatic aneurysms with a diameter > 55mm in men and > 50 mm in woman Aneurysm-growth exceeds 10mm/year Patient requires at least one cannulation during which requires at least one cannulation (e.g. fenestration of endograft, side-branch and/or contralateral leg of endograft) Exclusion Criteria: Patient is generally contraindicated for EVAR Patient requires an emergency surgery Patient with an increased risk of aneurysm rupture or saccular aneurysm, aneurysm with isolated wall protuberances or penetrating aortic ulcer Patient with a dissecting acutely ruptured or leaking aneurysm or an acute vascular injury caused by a trauma Patient with stroke or transient ischemic attack (TIA) within the last 6 months prior to baseline Patient with myocardial infarction (MI) with the last 3 months prior to baseline Patient with acute or chronic renal failure (including dialysis); Creatinine > 2.00 mg/dl or > 182 µmol/L Patient with co-morbidities that constitutes an unacceptable risk (for example chronic obstructive pulmonary disease (COPD), liver failure, immunosuppression, polyneuropathy and hematological diseases) Patient with bleeding history or coagulopathy Patient with contraindication or allergies to take anticoagulants, antiplatelet drugs or contrast media Life expectancy of less than 5 years Female patient that is pregnant, is planning on becoming pregnant in the next month or is breastfeeding Patient with inability to obtain vascular access Patient has an active local or systemic infection Patient is currently participating in another investigational study where the endpoints have not yet been achieved Patient has a mental illness, and/or been diagnosed as clinically depressed or belongs to a vulnerable population (e.g., prisoner, severe drug abuser, developmentally disabled) that would compromise the ability to provide informed consent. Patient has an obstructed or inadequate vasculature by means of tortuous anatomy hindering the TC catheter to reach target orifice(s) Patient has an elevated risk of plaque dislodgment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hubert Schelzig, Prof. Dr.
Organizational Affiliation
Heinrich-Heine University, Duesseldorf
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitätsklinikum RWTH Aachen
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Facility Name
Heinrich-Heine University Düsseldorf
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
Facility Name
Universitäres Herzzentrum Hamburg
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Facility Name
Universitätklinikum Leipzig
City
Leipzig
ZIP/Postal Code
04103
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Application of the Medyria TrackCath System in Endovascular Repair of Abdominal Aortic Aneurysms (AAA)

We'll reach out to this number within 24 hrs